Deep Genomics Inc.

Venture capital mega-rounds of $100m or more are driving record levels of VC investment in biopharmaceutical companies, and these big financings have not taken a summer break. [Sidebar#SC144714] The l

Venture capital investors have not taken the summer off, at least not during the first few weeks of June, continuing to support mega-rounds of $100m or more for biopharmaceutical companies with novel

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Teams With Precision On DMD, Gene